Drilldown: Medicines

None (1)

Leqembi (1)

Anti-amyloid beta (Aβ) monoclonal antibody (1) · targets protofibrils (1)

None (1)

Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1)

10 mg/kg IV every 2 weeks (1)

200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1)

10 mg/kg q2w (1)

IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

Ongoing dosing (1)

~5-7 days (1)

100% (IV) (1)

Limited data (1)

Rx; REMS-like program for ARIA monitoring (1)